JPMorgan Chase & Co. Acquires 1,191 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

JPMorgan Chase & Co. grew its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 2.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,565 shares of the biotechnology company’s stock after acquiring an additional 1,191 shares during the quarter. JPMorgan Chase & Co. owned about 0.05% of Anavex Life Sciences worth $242,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of AVXL. Nwam LLC purchased a new position in Anavex Life Sciences in the 3rd quarter worth approximately $5,172,000. Barclays PLC lifted its holdings in shares of Anavex Life Sciences by 70.4% during the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 64,101 shares during the last quarter. Geode Capital Management LLC grew its position in Anavex Life Sciences by 2.8% in the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares in the last quarter. Squarepoint Ops LLC bought a new position in Anavex Life Sciences in the second quarter valued at $191,000. Finally, Marshall Wace LLP bought a new stake in Anavex Life Sciences during the second quarter worth about $166,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AVXL. HC Wainwright reiterated a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday. D. Boral Capital reiterated a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Tuesday.

Anavex Life Sciences Trading Down 3.1 %

Shares of NASDAQ:AVXL opened at $9.27 on Friday. The stock has a market capitalization of $786.28 million, a P/E ratio of -17.83 and a beta of 0.70. The stock’s 50-day moving average price is $9.99 and its 200-day moving average price is $7.55. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, research analysts predict that Anavex Life Sciences Corp. will post -0.73 EPS for the current year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.